Journal
GASTROENTEROLOGY
Volume 160, Issue 2, Pages 524-537Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2020.09.056
Keywords
Intestinal Microbiome; Host-Microbe Interactions; Colitis; Mucosal Inflammation; Dysbiosis
Categories
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases [RC2DK122394, R01DK47722, R01DK113788]
- NIH [T32 DK07074]
- Center for Interdisciplinary Study of Inflammatory Intestinal Diseases [P30 DK42086]
- Gastrointestinal Research Foundation of Chicago
- David and Ellen Horing Research Fund
- Helmsley Charitable Trust
Ask authors/readers for more resources
Inflammatory bowel diseases (IBD) result from the interaction of environmental, microbial, immunological, and genetic factors, with alterations in the gut microbiota playing a role in their development and progression. The use of microbiome-based therapies can potentially prevent, manage, and cure IBD, bridging the gap between basic sciences and clinical application through research findings.
Inflammatory bowel diseases (IBD) develop via convergence of environmental, microbial, immunological, and genetic factors. Alterations in the gut microbiota have been associated with development and progression of IBD, but it is not clear which populations of microbes are involved or how they might contribute to IBD. We review the genetic and environmental factors affecting the gut microbiota, the roles of gut microbes and their bioproducts in the development and clinical course of IBD, and strategies by which microbiome-based therapies can be used to prevent, manage, and eventually cure IBD. We discuss research findings that help bridge the gap between the basic sciences and clinical application.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available